BioCardia
125 Shoreway Road, Suite B
San Carlos
California
94070
United States
(650) 226-0120
(650) 631-3731
info@biocardia.com

Related Content

CardiAMP cell therapy-treated patients had 37% relative risk reduction in heart death equivalent (death, heart transplant, left ventricular assist device implantation) and 9% relative risk reduction in non-fatal major adverse cardiac and cerebrovascular events
News | FDA
Biocardia Reports Positive Interim Results from Phase III Cardiamp Cell Therapy Heart Failure Trial, with Compelling Data in Subgroup with Elevated NTproBNP Biomarker for Heart Failure

March 7, 2024 — BioCardia, Inc. , a biotechnology company focused on advancing late-stage cell therapy interventions for ...

Home March 07, 2024
arrow
BioCardia, Inc., a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary disease, today announced that the first patient was enrolled and treated in its CardiALLO Allogeneic Mesenchymal Cell Therapy Phase I/II trial
News | Cardiovascular Clinical Studies
BioCardia Doses First Patient in CardiALLO Phase I/II Clinical Trial of BCDA-03 Allogeneic Mesenchymal Stem Cells for the Treatment of Ischemic Heart Failure of Reduced Ejection Fraction

December 19, 2023 — BioCardia, Inc., a developer of cellular and cell-derived therapeutics for the treatment of ...

Home December 19, 2023
arrow
Japan’s PMDA asked for further details on a number of elements included in BioCardia’s CardiAMP preclinical and clinical packages in order to gain approval.
News | Heart Failure
BioCardia Shares Update from Japan PMDA Consultation on CardiAMP Autologous Cell Therapy for Ischemic Heart Failure; Foreign Data Expected to be Sufficient for Product Approval

November 30, 2023 — BioCardia, Inc., a developer of cellular and cell-derived therapeutics for the treatment of ...

Home November 30, 2023
arrow
BioCardia announces that the Food and Drug Administration (FDA) has approved its proposed CardiAMP Heart Failure II study protocol
News | FDA
BioCardia Announces FDA Approval of CardiAMP Heart Failure II Protocol for Autologous Cell Therapy for Ischemic Heart Failure

November 17, 2023 — BioCardia, Inc., a developer of cellular and cell-derived therapeutics for the treatment of ...

Home November 17, 2023
arrow
Novel platform for structural heart interventions now in human use, with ability to improve patient recovery and reduce anesthesia and hospital stays
News | Cardiovascular Clinical Studies
BioCardia Announces Completion of Enrollment in Phase III CardiAMP HF Trial and Plans for CardiAMP HF Trial II

October 12, 2023 — BioCardia, Inc., a developer of cellular and cell-derived therapeutics for the treatment of ...

Home October 12, 2023
arrow
the Company is exploring development of a new Phase III clinical trial protocol
News | Heart Failure
BioCardia Announces Clarification and Next Steps on its Autologous CardiAMP Cell Therapy Programs

September 8, 2023 — BioCardia, Inc., a developer of cellular and cell-derived therapeutics for the treatment of ...

Home September 08, 2023
arrow
BioCardia, Inc., a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary disease, announced that the independent Data Safety Monitoring Board (DSMB) has completed its prespecified data review for the ongoing Phase III pivotal CardiAMP Cell Therapy Heart Failure Trial
News | Cardiovascular Clinical Studies
BioCardia Announces DSMB Recommendation to Pause New Enrollment in Phase III Pivotal CardiAMP Cell Therapy Heart Failure Trial While Additional Blinded Data is Collected

July 24, 2023 — BioCardia, Inc., a developer of cellular and cell-derived therapeutics for the treatment of ...

Home July 24, 2023
arrow
BioCardia's CardiAMP cell therapy uses a patient’s own (autologous) bone marrow cells delivered to the heart in a minimally invasive, catheter-based procedure to potentially stimulate the body’s natural healing response. The therapy incorporates a pre-procedural screening assay to identify those patients who are likely responders to the therapy, a first for a cardiac cell therapy. 
News | Stem Cell Therapies
BioCardia Announces First Patient Treated in CardiAMP Cell Therapy Trial for Chronic Myocardial Ischemia

October 28, 2021 – The first patient has been treated in a new trial using stem cell therapy to treat chronic myocardial ...

Home October 28, 2021
arrow
BioCardia Announces CardiAMP Heart Failure Pivotal Trial Continues with First Patient Randomized in COVID-19 Era
News | Heart Failure
BioCardia Resumes Cases in the CardiAMP Heart Failure Trial

June 30, 2020 — BioCardia, Inc. announced that the company has resumed cases in the CardiAMP Heart Failure Trial. The ...

Home June 30, 2020
arrow
BioCardia Initiates Commercial Release of Avance Steerable Introducer
News | Catheters
BioCardia Initiates Commercial Release of Avance Steerable Introducer

October 23, 2019 — BioCardia announced the U.S. commercial availability of its Avance Bi-Directional Steerable ...

Home October 23, 2019
arrow
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now